GSK ：Nuvalent is being acquired for $10.6 billion.
Nuvalent has been announced to be acquired by GlaxoSmithKline (GSK) on June 9 for $10.6 billion, with an anticipated purchase price of $124 per share, representing a 40% premium over the recent closing price. Nuvalent is a Boston-based clinical-stage biopharmaceutical company focused on developing precision targeted oncology therapies.
The transaction includes three novel lung cancer drugs. Among them, Zidesamtinib (NVL-520) is a next-generation ROS1 inhibitor that has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA. In August 2025, the drug was submitted for marketing approval to the FDA for the treatment of non-small cell lung cancer (NSCLC), with a Prescription Drug User Fee Act (PDUFA) target action date of September 18, 2026.
Neladalkib (NVL-655) is a next-generation ALK inhibitor. In April of this year, the FDA accepted its marketing application for the treatment of NSCLC, with a PDUFA target action date of November 27, 2026. This drug has also received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA.
The third product, NVL-330, is a HER2 inhibitor currently in Phase I clinical trials for HER2-mutant non-small cell lung cancer. Additionally, the acquisition includes multiple preclinical programs from Nuvalent.
Buy NVL-520/NVL-655/NVL-330 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
